Your browser doesn't support javascript.
loading
Early-stage Burkitt lymphoma remained in remission 7 years from diagnosis after only one cycle of chemoimmunotherapy.
Al Sbihi, Ali; Manasrah, Nouraldeen; Sano, Dahlia; Lonardo, Sarah.
Afiliação
  • Al Sbihi A; Internal Medicine, Sinai Grace Hospital, Detroit, Michigan, USA aalsbihi@dmc.org.
  • Manasrah N; Internal Medicine, Sinai Grace Hospital, Detroit, Michigan, USA.
  • Sano D; Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.
  • Lonardo S; Hematopathology, Harper University Hospital, Detroit, Michigan, USA.
BMJ Case Rep ; 14(4)2021 Apr 20.
Article em En | MEDLINE | ID: mdl-33879463
Burkitt lymphoma (BL) is a rare, mature, fast-growing and highly aggressive B-cell neoplasm. It has a high-proliferation rate with distinctive genetic changes in the C-MYC oncogene. Treatment usually requires intense and frequent chemotherapy regimens with central nervous system prophylaxis as the usual regimens used for other non-Hodgkin's lymphoma yield poor survival in BL. This report discusses a patient who was diagnosed with a stage II, high-grade BL who received one cycle of intense chemotherapy and refused further treatment. That patient remained in complete remission in his last follow-up; 7 years from diagnosis without requiring other therapies for his lymphoma.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Linfoma de Burkitt Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: BMJ Case Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Linfoma de Burkitt Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: BMJ Case Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido